129 related articles for article (PubMed ID: 21550659)
1. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells.
Tanaka N; Wang YH; Shiseki M; Takanashi M; Motoji T
Leuk Res; 2011 Sep; 35(9):1219-25. PubMed ID: 21550659
[TBL] [Abstract][Full Text] [Related]
2. PRAME promotes in vitro leukemia cells death by regulating S100A4/p53 signaling.
Xu Y; Rong LJ; Meng SL; Hou FL; Zhang JH; Pan G
Eur Rev Med Pharmacol Sci; 2016; 20(6):1057-63. PubMed ID: 27049257
[TBL] [Abstract][Full Text] [Related]
3. Expression and prognostic relevance of PRAME in primary osteosarcoma.
Tan P; Zou C; Yong B; Han J; Zhang L; Su Q; Yin J; Wang J; Huang G; Peng T; Shen J
Biochem Biophys Res Commun; 2012 Mar; 419(4):801-8. PubMed ID: 22390931
[TBL] [Abstract][Full Text] [Related]
4. Silencing HCCR2 expression inhibits the proliferation of leukemia cells by inducing apoptosis and promoting cell cycle arrest.
Qiao SK; Ren HY; Shi YJ; Liu W
Int J Mol Med; 2013 Dec; 32(6):1373-9. PubMed ID: 24126909
[TBL] [Abstract][Full Text] [Related]
5. PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo.
Xu Y; Yue Q; Wei H; Pan G
Int J Clin Exp Pathol; 2015; 8(11):14549-55. PubMed ID: 26823776
[TBL] [Abstract][Full Text] [Related]
6. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17).
Bullinger L; Schlenk RF; Götz M; Botzenhardt U; Hofmann S; Russ AC; Babiak A; Zhang L; Schneider V; Döhner K; Schmitt M; Döhner H; Greiner J
Clin Cancer Res; 2013 May; 19(9):2562-71. PubMed ID: 23444226
[TBL] [Abstract][Full Text] [Related]
7. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of PRAME enhances adriamycin-induced apoptosis in chronic myeloid leukemia cells.
Yan H; Zhao RM; Wang ZJ; Zhao FR; Wang SL
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(24):4827-34. PubMed ID: 26744874
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo.
Tajeddine N; Gala JL; Louis M; Van Schoor M; Tombal B; Gailly P
Cancer Res; 2005 Aug; 65(16):7348-55. PubMed ID: 16103086
[TBL] [Abstract][Full Text] [Related]
10. PRAME: from diagnostic marker and tumor antigen to promising target of RNAi therapy in leukemic cells.
Yin B
Leuk Res; 2011 Sep; 35(9):1159-60. PubMed ID: 21592570
[No Abstract] [Full Text] [Related]
11. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.
Elmaagacli AH; Koldehoff M; Peceny R; Klein-Hitpass L; Ottinger H; Beelen DW; Opalka B
Haematologica; 2005 Mar; 90(3):326-34. PubMed ID: 15749664
[TBL] [Abstract][Full Text] [Related]
12. Effects of exogenous agmatine in human leukemia HMC-1 and HL-60 cells on proliferation, polyamine metabolism and cell cycle.
Haenisch B; Bönisch H; Cichon S; Allam JP; Novak N; Molderings GJ
Leuk Res; 2011 Sep; 35(9):1248-53. PubMed ID: 21236489
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies.
Schenk T; Stengel S; Goellner S; Steinbach D; Saluz HP
Genes Chromosomes Cancer; 2007 Sep; 46(9):796-804. PubMed ID: 17534929
[TBL] [Abstract][Full Text] [Related]
15. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma.
Proto-Siqueira R; Figueiredo-Pontes LL; Panepucci RA; Garcia AB; Rizzatti EG; Nascimento FM; Ishikawa HC; Larson RE; Falcão RP; Simpson AJ; Gout I; Filonenko V; Rego EM; Zago MA
Leuk Res; 2006 Nov; 30(11):1333-9. PubMed ID: 16620968
[TBL] [Abstract][Full Text] [Related]
16. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
[TBL] [Abstract][Full Text] [Related]
17. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
18. Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells.
Wang X; Ren J; Qu X
ChemMedChem; 2008 Jun; 3(6):940-5. PubMed ID: 18286553
[TBL] [Abstract][Full Text] [Related]
19. Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo.
Tajeddine N; Louis M; Vermylen C; Gala JL; Tombal B; Gailly P
Leuk Lymphoma; 2008 Jun; 49(6):1123-31. PubMed ID: 18452107
[TBL] [Abstract][Full Text] [Related]
20. Childhood acute myelogenous leukaemia: association between PRAME, apoptosis- and MDR-related gene expression.
Goellner S; Steinbach D; Schenk T; Gruhn B; Zintl F; Ramsay E; Saluz HP
Eur J Cancer; 2006 Nov; 42(16):2807-14. PubMed ID: 16978861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
